MX2018014407A - Estabilizacion de formulaciones de acido beta-hidroxiisovalerico en capsulas de gel blando. - Google Patents
Estabilizacion de formulaciones de acido beta-hidroxiisovalerico en capsulas de gel blando.Info
- Publication number
- MX2018014407A MX2018014407A MX2018014407A MX2018014407A MX2018014407A MX 2018014407 A MX2018014407 A MX 2018014407A MX 2018014407 A MX2018014407 A MX 2018014407A MX 2018014407 A MX2018014407 A MX 2018014407A MX 2018014407 A MX2018014407 A MX 2018014407A
- Authority
- MX
- Mexico
- Prior art keywords
- beta
- soft gel
- hydroxyisovaleric acid
- stabilization
- gel capsules
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- RWBRUCCWZPSBFC-UHFFFAOYSA-N 17-(1-hydroxyethyl)-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one Chemical compound C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C(O)C)C1(C)CC2 RWBRUCCWZPSBFC-UHFFFAOYSA-N 0.000 title abstract 3
- AXFYFNCPONWUHW-UHFFFAOYSA-N beta-hydroxy-beta-methyl butyric acid Natural products CC(C)(O)CC(O)=O AXFYFNCPONWUHW-UHFFFAOYSA-N 0.000 title abstract 3
- 239000002775 capsule Substances 0.000 title abstract 3
- 238000009472 formulation Methods 0.000 title 1
- 230000006641 stabilisation Effects 0.000 title 1
- 238000011105 stabilization Methods 0.000 title 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 abstract 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 abstract 1
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 abstract 1
- 239000004381 Choline salt Substances 0.000 abstract 1
- 229960001456 adenosine triphosphate Drugs 0.000 abstract 1
- 229960003237 betaine Drugs 0.000 abstract 1
- 229960004203 carnitine Drugs 0.000 abstract 1
- 235000019417 choline salt Nutrition 0.000 abstract 1
- 229960004956 glycerylphosphorylcholine Drugs 0.000 abstract 1
- 239000012669 liquid formulation Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 abstract 1
- 150000003248 quinolines Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662341464P | 2016-05-25 | 2016-05-25 | |
| PCT/US2017/034551 WO2017205673A1 (en) | 2016-05-25 | 2017-05-25 | Stabilization of beta-hydroxyisovaleric acid formulations in soft gel capsules |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018014407A true MX2018014407A (es) | 2019-02-21 |
Family
ID=60411620
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018014407A MX2018014407A (es) | 2016-05-25 | 2017-05-25 | Estabilizacion de formulaciones de acido beta-hidroxiisovalerico en capsulas de gel blando. |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US10959957B2 (enExample) |
| EP (1) | EP3463327B1 (enExample) |
| JP (1) | JP6929939B2 (enExample) |
| KR (1) | KR102384266B1 (enExample) |
| CN (2) | CN121177244A (enExample) |
| AU (1) | AU2017270219B2 (enExample) |
| CA (1) | CA3024584A1 (enExample) |
| CO (1) | CO2018014085A2 (enExample) |
| MX (1) | MX2018014407A (enExample) |
| MY (1) | MY199597A (enExample) |
| RU (1) | RU2018145520A (enExample) |
| WO (1) | WO2017205673A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111888325A (zh) * | 2020-08-04 | 2020-11-06 | 瑞希(重庆)生物科技有限公司 | 一种卡拉胶凝胶、药物赋形剂和皮肤外用制剂 |
| JP7750505B2 (ja) * | 2021-10-14 | 2025-10-07 | 中日本カプセル 株式会社 | カプセル及びカプセルの製造方法 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2870062A (en) * | 1956-04-27 | 1959-01-20 | Scherer Corp R P | Gelatin composition for capsules |
| US5200191A (en) | 1991-09-11 | 1993-04-06 | Banner Gelatin Products Corp. | Softgel manufacturing process |
| US5569466A (en) | 1995-05-17 | 1996-10-29 | R. P. Scherer Corporation | Fill compositions for soft elastic gel capsules |
| US6340473B1 (en) | 1999-07-07 | 2002-01-22 | R.P. Scherer Technologies, Inc. | Film forming compositions comprising modified starches and iota-carrageenan and methods for manufacturing soft capsules using same |
| DE10064312C2 (de) | 2000-12-22 | 2003-05-22 | Degussa | Cholinpyruvat-Hydrat, Verfahren zu dessen Herstellung, Cholinpyruvat-Hydrat enthaltende Formulierung sowie deren Verwendung |
| US7740878B2 (en) * | 2001-10-22 | 2010-06-22 | Danisco A/S | Use of betaine to enhance exercise performance |
| ATE374602T1 (de) | 2001-12-21 | 2007-10-15 | Supernus Pharmaceuticals Inc | Orale kapselformulierung mit verbesserter physikalischer stabilität |
| DE10208568A1 (de) | 2002-02-27 | 2003-09-18 | Degussa Bioactives Deutschland | Verbindung, enthaltend Kreatin, eine Säure-Komponente und/oder einen Komplex-Bildner |
| DE10217557A1 (de) | 2002-04-19 | 2003-11-06 | Degussa Bioactives Gmbh | Funktionsnahrungsmittel enthaltend eine Phospholipid-haltige stabile Matrix |
| US20050215640A1 (en) | 2004-03-26 | 2005-09-29 | Baxter Jeffrey H | HMB compositions and uses thereof |
| US8231896B2 (en) * | 2004-11-08 | 2012-07-31 | R.P. Scherer Technologies, Llc | Non-gelatin soft capsule system |
| DE102004060914A1 (de) | 2004-12-17 | 2006-07-06 | Bioghurt Biogarde Gmbh & Co. Kg | Verwendung von Liponsäure-haltigen Cyclodextrin-Komplexen |
| EP2242489A1 (en) * | 2005-02-15 | 2010-10-27 | Jallal Messadek | Combination therapeutic compositions and method of use |
| DE102005061765A1 (de) | 2005-05-19 | 2006-11-23 | Degussa FreshTech Beverages LLC, Milwaukee | Füllmaterial für einen Getränkebehälter |
| CN101574146B (zh) * | 2008-05-07 | 2012-06-13 | 北京康比特体育科技股份有限公司 | 一种含有hmb的运动营养补剂 |
| JP2009153529A (ja) * | 2009-04-17 | 2009-07-16 | Tsujido Chemical Corp | 食品組成物 |
| ES2608483T3 (es) * | 2009-12-18 | 2017-04-11 | Metabolic Technologies, Inc. | Método mejorado de administración de beta-hidroxi-beta-metilbutirato (HMB) |
| CN103338658A (zh) | 2010-12-22 | 2013-10-02 | 雅培制药有限公司 | 含有β-羟基-β甲基丁酸钙和共轭亚油酸的营养型产品 |
| MX2014000419A (es) * | 2011-07-15 | 2014-09-22 | Nusirt Sciences Inc | Composicones y metodos para modular trayectorias metabolicas. |
| BR112015005199B1 (pt) | 2012-09-10 | 2022-09-06 | Metabolic Technologies, Inc | Composição, e, método para fornecer um benefício a um animal em necessidade do mesmo |
| BR112015010947A2 (en) | 2012-11-13 | 2018-06-05 | Nusirt Sciences, Inc. | compositions and methods for increasing energy metabolism. |
| US20140272000A1 (en) | 2013-03-14 | 2014-09-18 | Metabolic Technologies, Inc. | Liquids and Foodstuffs Containing beta-hydroxy-beta-methylbutyrate (HMB) in the Free Acid Form and Methods of Manufacturing or Producing the Same |
| JP6389237B2 (ja) * | 2013-03-15 | 2018-09-12 | パセオン ソフトジェルズ インコーポレイティド | 非ゼラチン性腸溶性軟質カプセル |
| HK1221609A1 (zh) | 2013-05-01 | 2017-06-09 | Abbott Laboratories | 增强老化肌肉再生的方法 |
| EP3082778B1 (en) * | 2013-12-18 | 2019-04-03 | Capsugel Belgium NV | Stable liquid filled hard capsule comprising beta-hydroxy-beta-methylbutyric acid |
| WO2015195990A1 (en) * | 2014-06-20 | 2015-12-23 | Banner Life Sciences Llc | Liquid-filled immediate release soft gelatin capsules |
| JP2018090504A (ja) * | 2016-11-30 | 2018-06-14 | 株式会社東洋新薬 | 筋肉増強用組成物 |
-
2017
- 2017-05-25 RU RU2018145520A patent/RU2018145520A/ru not_active Application Discontinuation
- 2017-05-25 JP JP2019514190A patent/JP6929939B2/ja active Active
- 2017-05-25 CA CA3024584A patent/CA3024584A1/en active Pending
- 2017-05-25 AU AU2017270219A patent/AU2017270219B2/en active Active
- 2017-05-25 MY MYPI2018002008A patent/MY199597A/en unknown
- 2017-05-25 WO PCT/US2017/034551 patent/WO2017205673A1/en not_active Ceased
- 2017-05-25 MX MX2018014407A patent/MX2018014407A/es unknown
- 2017-05-25 KR KR1020187037387A patent/KR102384266B1/ko active Active
- 2017-05-25 US US15/605,664 patent/US10959957B2/en active Active
- 2017-05-25 CN CN202511046150.0A patent/CN121177244A/zh active Pending
- 2017-05-25 CN CN201780031975.2A patent/CN109562087A/zh active Pending
- 2017-05-25 EP EP17803618.2A patent/EP3463327B1/en active Active
-
2018
- 2018-12-24 CO CONC2018/0014085A patent/CO2018014085A2/es unknown
-
2021
- 2021-03-30 US US17/217,913 patent/US12133920B2/en active Active
-
2024
- 2024-11-04 US US18/936,798 patent/US20250057773A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3463327B1 (en) | 2024-04-17 |
| JP2019517576A (ja) | 2019-06-24 |
| JP6929939B2 (ja) | 2021-09-01 |
| EP3463327A1 (en) | 2019-04-10 |
| US12133920B2 (en) | 2024-11-05 |
| RU2018145520A (ru) | 2020-06-25 |
| KR102384266B1 (ko) | 2022-04-06 |
| EP3463327A4 (en) | 2020-01-22 |
| AU2017270219A1 (en) | 2018-11-29 |
| AU2017270219B2 (en) | 2023-03-16 |
| US20170340572A1 (en) | 2017-11-30 |
| BR112018073949A2 (pt) | 2019-02-26 |
| EP3463327C0 (en) | 2024-04-17 |
| RU2018145520A3 (enExample) | 2020-08-26 |
| CA3024584A1 (en) | 2017-11-30 |
| US10959957B2 (en) | 2021-03-30 |
| US20250057773A1 (en) | 2025-02-20 |
| BR112018073949A8 (pt) | 2023-03-21 |
| US20210212953A1 (en) | 2021-07-15 |
| MY199597A (en) | 2023-11-08 |
| WO2017205673A1 (en) | 2017-11-30 |
| KR20190021259A (ko) | 2019-03-05 |
| CO2018014085A2 (es) | 2019-03-18 |
| CN121177244A (zh) | 2025-12-23 |
| CN109562087A (zh) | 2019-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020550341A1 (en) | Niraparib formulations | |
| CR20210281A (es) | Compuestos, composiciones farmacéuticas y métodos de preparación de compuestos y de uso como inhibidores de la cinasa atr | |
| IN2015MU00865A (enExample) | ||
| EA201892395A1 (ru) | Лекарственные составы ингибитора lsd1 | |
| MX380798B (es) | Profármacos de alvocidib que tienen una biodisponibilidad aumentada. | |
| BR112017004032A2 (pt) | formulação tópica | |
| SA518400552B1 (ar) | مركبات فوسفوراميدات | |
| MA39765A (fr) | Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation | |
| MX2017015238A (es) | Composicion oral de celecoxib para tratamiento de dolor. | |
| MX2018000143A (es) | Composiciones nutritivas que contienen fosfatidiletanolamina, esfingomielina y acido docosahexaenoico. | |
| MX389336B (es) | Formulacion farmaceutica. | |
| PH12016501519B1 (en) | Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions | |
| EA201891337A2 (ru) | Фармацевтическая композиция от нейропатической боли | |
| MX385518B (es) | FORMULACIÓN QUE TIENE CARACTERÍSTICAS MEJORADAS DE LIBERACIÓN DE FÁRMACOS pH DEPENDIENTES, QUE CONTIENEN ESOMEPRAZOL O UNA DE SUS SALES FARMACÉUTICAS ACEPTABLE. | |
| WO2016001905A3 (en) | Stable liquid ready-to-use injectable formulation of bortezomib | |
| MY199597A (en) | Stabilization of beta-hydroxyisovaleric acid formulations in soft gel capsules | |
| EA201792237A1 (ru) | Фармацевтические составы | |
| MX2022013450A (es) | Formulaciones farmaceuticas. | |
| MX2025015454A (es) | Formulaciones/composiciones que comprenden ibrutinib | |
| EA201991286A1 (ru) | Твердая фармацевтическая композиция для перорального применения, содержащая тенофовир и эмтрицитабин | |
| PH12020500022A1 (en) | Salt of (ss)-adenosyl methionine with inositol hexaphosphate, and process for the preparation thereof | |
| CL2019000123A1 (es) | Preparaciones de vitaminas que contienen galato de propilo. | |
| MX393915B (es) | Nuevas formulaciones orales de belinostat. | |
| WO2018069805A3 (en) | Method for preparation of liquid oral composition of l-thyroxin | |
| EP4537846A3 (en) | Anavex2-73 for the treatment of alzheimer s disease |